[Cardioprotective, inotropic, and anti-arrhythmia properties of a complex adaptogen "Tonizid"].
We have studied the new complex plant adaptogen preparation tonizid containing dry extracts of Aralia mandshurica, Panax ginseng, Rhodiola rosea, and Eleutherococcus senticosus. The course administration (5 days) of tonizid led to a decrease in the ratio of necrotic zone size/risk area during a 45-min local ischemia and a 2-hr reperfusion in artificially ventilated chloralose anaesthetized rats. This compound decreased the necrotic zone but did not change the size of the risk area. Tonizid also prevented an appearance of ventricular fibrillation during a 45-min coronary artery occlusion, but did not affect the incidence of ventricular arrhythmias during a brief ischemia and reperfusion. In a separate series of experiments, tonizid was administered during 5 days to rats with postinfarction cardiac sclerosis, which was formed 45 days after coronary artery occlusion. In this case, tonizid dose-dependently elevated the ventricular fibrillation threshold. The experiments in vitro were performed on a model of 35-min total ischemia and 30-min reperfusion of isolated rat heart using the Langendorff technique. The course administration of tonizid attenuated the reperfusion-induced decrease in the left ventricular pressure and the rate of contraction. However, tonizid did not prevent a reperfusion-induced reduction in the heart rate, a decrease in the rate of relaxation, and an increase in the final diastolic pressure. Tonizid decreased the creatine kinase levels in the venous effluent from isolated rat heart during reperfusion. At the same time, the plant adaptogen did not affect the incidence of ventricular arrhythmias and coronary flow. It is suggested that tonizid can be used as an adaptogen drug attenuating the contractility dysfunction and preventing an appearance of irreversible cardiomyocyte damage during ischemia and reperfusion. Tonizid exhibits cardioprotective and antifibrillatory properties during acute cardiac ischemia/reperfusion and postinfarction cardiac fibrosis.
Lishmanov
Iu B
IuB
Maslov
L N
LN
Arbuzov
A G
AG
Krylatov
A V
AV
Platonov
A A
AA
Burkova
V N
VN
Kaiumova
E A
EA
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006321:Heart; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D009200:Myocardial Contraction / Q000187:drug effects*; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D009206:Myocardium / Q000473:pathology; D010936:Plant Extracts / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012598:Sclerosis; D014693:Ventricular Fibrillation / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; D002316:Cardiotonic Agents; D010936:Plant Extracts